LCZ696 Catalog No.:M8445-2 Chemical Name: methyl (3S)-3-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]propanamido]-5-fluoro-4-oxopentanoate

Chemical Name: methyl (3S)-3-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]propanamido]-5-fluoro-4-oxopentanoate

1028969-49-4 (MCOPPB free base)

5 mg/kg dissolved in 0

Smiles: CC1=NC(=CS1)/C=C(\C)/[C@@H]1C[C@@H]2O[C@@H]2CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1

It reduces plasma levels of total cholesterol

LCZ696 Catalog No.:M8445-2 Chemical Name: methyl (3S)-3-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]propanamido]-5-fluoro-4-oxopentanoateLCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1: 1 molar ratio. As of 2014 it is being developed by Novartis. LCZ696 is co crystallized valsartan and sacubitril, in a one to one molar ratio. According to Sci Finder database, LCZ696 has a formula as (valsartan)(sacubitril)(3Sodium)(5 2 hydrate), or (2 valsartan)(2 sacubitril) (6 Sodium)(5 hydrate),